Shares of Baudax Bio (NASDAQ:BXRX) have been given a consensus broker rating score of 1.00 (Strong Buy) from the three analysts that cover the stock, Zacks Investment Research reports. Three research analysts have rated the stock with a strong buy recommendation.
Analysts have set a 12-month consensus price objective of $15.00 for the company and are predicting that the company will post ($0.94) EPS for the current quarter, according to Zacks. Zacks has also given Baudax Bio an industry rank of 97 out of 255 based on the ratings given to its competitors.
A number of equities research analysts have recently weighed in on BXRX shares. Janney Montgomery Scott started coverage on Baudax Bio in a research note on Friday, November 22nd. They issued a “buy” rating and a $12.00 price objective for the company. Piper Jaffray Companies began coverage on Baudax Bio in a report on Friday, November 22nd. They issued an “overweight” rating and a $12.00 target price for the company. Piper Sandler lifted their price target on Baudax Bio from to in a report on Friday, February 21st. ValuEngine downgraded Baudax Bio from a “buy” rating to a “hold” rating in a report on Tuesday, December 24th. Finally, Zacks Investment Research downgraded Baudax Bio from a “buy” rating to a “hold” rating in a report on Thursday, February 20th.
About Baudax Bio
There is no company description available for Baudax Bio Inc
Featured Story: What are gap-down stocks?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Baudax Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baudax Bio and related companies with MarketBeat.com's FREE daily email newsletter.